Sarepta, Dyne sink after Novartis muscle disorder trial failure

Novartis AG

08/09/2026 11:42

** Shares of companies developing drugs for a muscle wasting disorder tumble in premarket trading after Novartis NOVN.S says its treatment failed the main goal of video hand-opening time, a measure of hand myotonia, in a late-stage trial
** Sarepta Therapeutics SRPT.O down 13.2% at $19.54, Dyne Therapeutics DYN.O drop 26% to $17.96
** U.S.-listed shares of Novartis were down 12.1% at $140.68 premarket     
** "The NVS failure makes Dyne's own trial much more risky. SRPT's drug is earlier stage, but the same goes there," - Cantor Fitzgerald analyst Eric Schmidt
** "For DYN, while the clinical risk here does go up, the upside potential for the stock goes up too, DYN now has a chance at being first-to-market in DM1," - Stifel  
** Up to last close, SRPT up 4.6%, DYN up 24.1% YTD   

 (Reporting by Sneha S K and Sriparna Roy)
 ((Sneha.SK@thomsonreuters.com;))